Astrazeneca PLC (AZN) Shares Sold by GFS Advisors LLC
GFS Advisors LLC cut its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 25.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,225 shares of the company’s stock after selling 10,408 shares during the quarter. GFS Advisors LLC’s holdings in Astrazeneca PLC were worth $1,058,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in AZN. Meeder Asset Management Inc. purchased a new stake in shares of Astrazeneca PLC during the 2nd quarter valued at $105,000. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after acquiring an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after acquiring an additional 1,769 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Astrazeneca PLC by 18.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after acquiring an additional 846 shares during the period. Finally, Westport Asset Management Inc. bought a new position in shares of Astrazeneca PLC during the 2nd quarter worth $170,000. 14.16% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Astrazeneca PLC (AZN) Shares Sold by GFS Advisors LLC” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/15/astrazeneca-plc-azn-shares-sold-by-gfs-advisors-llc.html.
AZN has been the subject of several research reports. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 22nd. Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Leerink Swann downgraded Astrazeneca PLC from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $36.00 to $31.00 in a research note on Thursday, July 27th. Argus reiterated a “buy” rating and set a $35.00 price target on shares of Astrazeneca PLC in a research note on Friday, September 1st. Finally, BMO Capital Markets set a $38.00 price target on Astrazeneca PLC and gave the stock a “buy” rating in a research note on Wednesday. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $34.20.
Shares of Astrazeneca PLC (NYSE AZN) traded up $0.34 on Wednesday, hitting $33.25. The stock had a trading volume of 2,914,200 shares, compared to its average volume of 4,841,029. The company has a market cap of $82,760.00, a P/E ratio of 7.85, a PEG ratio of 2.84 and a beta of 0.79. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. Astrazeneca PLC had a return on equity of 34.02% and a net margin of 15.90%. Astrazeneca PLC’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $1.32 EPS. equities research analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.
Astrazeneca PLC Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.